Curasan AG

curasan AG: REVOIS® All-in-One Dental Implant System Registered in the U.S.

@@start.t1@@--------------------------------------------------------------------------------   ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for   the content of this announcement. --------------------------------------------------------------------------------@@end@@

new product

Kleinostheim (euro adhoc) - curasan AG, a German leader in regenerative medicine, has obtained FDA clearance for its REVOIS® All-in-One dental implant system, permitting the sale of the system in the U.S. This means that the system can be rolled out earlier than originally planned - the rollout will take place at the ICOI World Congress in San Francisco in late August 2007.

REVOIS® gives curasan direct access to the dental implant market, the segment within dental surgery that generates the highest revenues and earnings. Curasan Inc., the company´s U.S. sales organization, has already been very successful in that country with its Cerasorb® synthetic bone substitute and its Epi-Guide® resorbable membrane. The excellent rapport with the target group, dental implantologists, and with opinion leaders that the company has established with these products are an excellent basis for marketing the REVOIS® All-in-One dental implant system.

"This step represents another important milestone in the implementation of our corporate strategy," said curasan´s CEO Hans Dieter Rössler. "This strategy calls on us to organize our sales and marketing activities with a clear focus on the dental market. Of course, our R&D department will continue to develop new products for use in orthopedics, for skin transplants and for other fields. These will be marketed by way of license agreements and by cooperation with multinational groups."

A Truly Useful Innovation: REVOIS® - the REVOlutionary Implant System - is an intelligent modular system that achieves maximum precision with a minimum number of parts, covering all implantological requirements with only 120 components. This simplifies procurement, allows the reduction of expensive inventory, and greatly enhances the component selection process in actual clinical practice.

One pivotal element is the multi-functional precision abutment. It fits all implant diameters and enables the user work with only one prosthetic line.

The REVOIS All-in-One System was designed for clinicians who demand highest quality and want to safely cover all implantological requirements with a single system but who, nevertheless, value simplicity of use and economical procedures as well as excellent precision and esthetics. Implantologists, prosthodontists and dental technicians can benefit from considerable savings in time and costs.

@@start.t2@@end of announcement                                                 euro adhoc 14.06.2007 09:26:04

ots Originaltext: Curasan AG
Im Internet recherchierbar:

Further inquiry note:
Kerstin Kornett
Telefon: +49(0)6027 4686-431

Branche: Biotechnology
ISIN:      DE0005494538
WKN:        549453
Index:    CDAX, Classic All Share, Prime All Share
Börsen:  Frankfurter Wertpapierbörse / regulated dealing/prime
              Börse Berlin-Bremen / free trade
              Hamburger Wertpapierbörse / free trade
              Baden-Württembergische Wertpapierbörse / free trade
              Börse Düsseldorf / free trade
              Niedersächsische Börse zu Hannover / free trade
              Bayerische Börse / free trade

Original-Content von: Curasan AG, übermittelt durch news aktuell

Weitere Meldungen: Curasan AG

Das könnte Sie auch interessieren: